AiPC (Ligand)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameAiPC (Ligand)
Drug Alias Nameandrogen-independent prostate cancer program (Ligand)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor modulators
TargetsAndrogen Receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLigand Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A